73 related articles for article (PubMed ID: 15034209)
1. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
Canaparo R; Casale F; Muntoni E; Zara GP; Della Pepa C; Berno E; Pons N; Fornari G; Eandi M
Br J Clin Pharmacol; 2000 Aug; 50(2):146-53. PubMed ID: 10930966
[TBL] [Abstract][Full Text] [Related]
2. Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation.
Van der Gaag S; Labots M; Swart EL; Crul M
Acta Oncol; 2024 Apr; 63():169-174. PubMed ID: 38597664
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of mesna in protection from cisplatin-induced ovarian damage in female rats.
Li X; Yang S; Lv X; Sun H; Weng J; Liang Y; Zhou D
J Gynecol Oncol; 2013 Apr; 24(2):177-85. PubMed ID: 23653836
[TBL] [Abstract][Full Text] [Related]
4. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
5. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
9. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs.
Sadowitz PD; Hubbard BA; Dabrowiak JC; Goodisman J; Tacka KA; Aktas MK; Cunningham MJ; Dubowy RL; Souid AK
Drug Metab Dispos; 2002 Feb; 30(2):183-90. PubMed ID: 11792689
[TBL] [Abstract][Full Text] [Related]
11. Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids.
Barnham KJ; Djuran MI; Murdoch PS; Ranford JD; Sadler PJ
Inorg Chem; 1996 Feb; 35(4):1065-1072. PubMed ID: 11666286
[TBL] [Abstract][Full Text] [Related]
12. Cellular accumulation determines the activity of three novel tricyclic platinum agents.
Gangopadhyay SB; Roendigs A; Kangarloo SB; Krebs B; Wolff JE
Anticancer Res; 2001; 21(3B):2039-43. PubMed ID: 11497295
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
